文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

与全因死亡率相关的医院获得性肺炎稳健亚型的识别与验证:多队列衍生与验证研究

Identification and validation of robust hospital-acquired pneumonia subphenotypes associated with all-cause mortality: a multi-cohort derivation and validation.
PubMed 文献 · Intensive Care Med · 2025-04-22
一句话结论在四个ICU队列中识别出两种HAP临床亚型,亚型2病情更重、28天死亡率和治疗失败率更高,且在VITAL试验中显示替唑胺疗效的效应修饰。

该研究基于法国PNEUMOCARE(n=511)、ATLANREA(n=401)、荷兰MARS(n=1351)和欧洲-南美ENIRRI(n=900)四个重症患者队列,用诊断时临床和常规生物学变量进行无监督聚类,发现两聚类模型拟合最佳。亚型2患者病情更重、体温更低、PaO2/FiO2更差,虽各队列患病率26.9%–66.9%不等,但28天死亡率和治愈检验时治疗失败率均持续高于亚型1(所有比较p<0.01)。亚型2与更严重的呼吸道微生态失调和更高促炎细胞因子水平相关,并在VITAL试验中显示替唑胺治疗失败的效应修饰(亚型1相对风险1.52,95%CI 1.12–2.06;亚型2相对风险0.98,95%CI 0.7–1.38)。作者认为这些亚型具有预后价值和未来临床试验预测性富集的潜力。

要点

  • 基于诊断时临床和常规生物学变量的无监督聚类,四个ICU队列一致支持HAP分为两个亚型。
  • 亚型2病情更重、体温更低、PaO2/FiO2更差,各衍生队列患病率26.9%–66.9%。
  • 亚型2的28天死亡率和治愈检验时治疗失败率持续高于亚型1(所有比较p<0.01)。
  • ATLANREA队列中亚型2呼吸道微生态失调更重、促炎细胞因子水平更高。
  • VITAL试验中亚型1替唑胺治疗失败相对风险1.52(95%CI 1.12–2.06),亚型2为0.98(95%CI 0.7–1.38),存在统计学显著效应修饰。

适用人群与场景

  • 四个重症患者队列:法国PNEUMOCARE(n=511)、ATLANREA(n=401),荷兰MARS(n=1351),欧洲-南美ENIRRI(n=900)。
  • 验证队列为国际随机临床试验VITAL(n=726),比较利奈唑胺与替唑胺治疗医院获得性肺炎。

研究设计与关键结果

  • 研究类型:多队列衍生与验证研究,基于诊断时临床和常规生物学变量进行无监督聚类,并用机器学习流程建立简化分类模型。
  • 测试十二种指标后确定两聚类模型最适合所有队列;亚型2较亚型1病情更重、体温更低、PaO2/FiO2更差。
  • 亚型2患病率在四个衍生队列为26.9%–66.9%,但28天死亡率和治愈检验时治疗失败率均持续高于亚型1(所有比较p<0.01)。
  • ATLANREA队列中亚型2与更重呼吸道微生态失调和更高促炎细胞因子水平相关。
  • VITAL试验中替唑胺治疗失败相对风险:亚型1为1.52(95%CI 1.12–2.06),亚型2为0.98(95%CI 0.7–1.38),效应修饰具统计学显著性。

证据类型、等级与局限

  • 证据类型:多队列衍生与验证研究,含四个观察性队列及一个国际随机临床试验验证队列。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为这些亚型具有预后价值,并可能在未来针对个体化治疗的临床试验中用于预测性富集。
  • VITAL试验中亚型1替唑胺治疗失败相对风险1.52(95%CI 1.12–2.06),亚型2为0.98(95%CI 0.7–1.38),提示替唑胺疗效可能因亚型而异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Despite optimal antimicrobial therapy, the treatment failure rate of hospital-acquired pneumonia (HAP) routinely reaches 40% in critically ill patients. Subphenotypes have been identified within sepsis and acute respiratory distress syndrome with important predictive and possibly therapeutic implications. We derived prognosis subphenotypes for HAP and explored whether they were associated with biological markers and response to treatment.

METHODS: We separately analysed data from four cohorts of critically ill patients in France (PNEUMOCARE, n = 511, ATLANREA, n = 401), Netherlands (MARS, n = 1351) and Europe-South America (ENIRRI, n = 900) to investigate HAP heterogeneity using unsupervised clustering based on clinical and routine biological variables available at HAP diagnosis. Then, we developed a machine learning-based workflow to create a simplified classification model using discovery data sets. This model was validated by applying it to an independent replication data set from an international randomized clinical trial comparing linezolid and tedizolid for the treatment of HAP (VITAL, n = 726 patients). The primary outcome was the association of subphenotypes with 28-day all-cause mortality. Secondary analyses included subphenotype associations with treatment failure at test-of-cure, respiratory microbiome and cytokine profiles in the ATLANREA subgroup, and treatment response in the VITAL trial.

RESULTS: We tested twelve metrics and determined that a two-cluster model best fits all cohorts. HAP subphenotype 2 had greater disease severity, lower body temperature, and worse PaO2/FiO2 ratio than subphenotype 1 patients. Although the prevalence of subphenotype 2 ranged from 26.9 to 66.9% across the four derivation cohorts, the rates of 28-day mortality and treatment failure at test-of-cure were consistently higher to subphenotype 1 (p < 0.01 for all comparisons). Subphenotype 2 was associated with greater respiratory microbiome dysbiosis and higher levels of proinflammatory cytokines in the ATLANREA cohort, as well as with statistically significant tedizolid effect modification in the VITAL trial (Relative Risk of treatment failure with tedizolid = 1.52; 95% CI 1.12-2.06 in subphenotype 1 vs. = 0.98; 95% CI 0.7-1.38 in subphenotype 2).

CONCLUSIONS: We identified two robust clinical subphenotypes by extensively analyzing HAP data sets. Their associations with respiratory microbiome composition, systemic inflammation, and treatment efficacy in independent data sets highlight their potential for prognostic value and predictive enrichment in future clinical trials aimed at personalized therapies.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Martin FP, Poulain C, Mulier JH, et al. Identification and validation of robust hospital-acquired pneumonia subphenotypes associated with all-cause mortality: a multi-cohort derivation and validation. Intensive Care Med. 2025. PMID: 40261385. doi:10.1007/s00134-025-07884-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。